Status:
TERMINATED
VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults
Lead Sponsor:
Vical
Conditions:
Invasive Aspergillosis
Invasive Pulmonary Aspergillosis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of the trial is to evaluate the safety and efficacy of a new antifungal with a novel mechanism of action in immunocompromised adults with invasive aspergillosis.
Detailed Description
To compare the safety and efficacy of VL-2397 to standard first-line treatment for invasive aspergillosis in immunocompromised adults with acute leukemia or recipients of an allogeneic hematopoietic c...
Eligibility Criteria
Inclusion
- Acute Leukemia (AML or ALL) patient or allo-HCT recipient with a diagnosis of IA
Exclusion
- Pregnant or breastfeeding
- IA involving sites other than lungs and sinuses
- Graft failure, acute or extensive chronic GvHD
- Uncontrolled diabetes
Key Trial Info
Start Date :
February 20 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 14 2019
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT03327727
Start Date
February 20 2018
End Date
January 14 2019
Last Update
February 27 2019
Active Locations (28)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham Hospital, Division of Infectious Diseases
Birmingham, Alabama, United States, 35233
2
UC San Diego Moores Cancer Center
La Jolla, California, United States, 92093
3
UC Davis Health, Dept. of Internal Medicine, Div. of Infectious Diseases
Sacramento, California, United States, 95817
4
Christiana Care Health Services, Department of Medicine
Newark, Delaware, United States, 19718